Condition (MeSH)
Nervous System Autoimmune Disease, Experimental
ClinicalTrials.gov lists 3 trials for Nervous System Autoimmune Disease, Experimental or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
4 sections measured, none recorded · 1 not measured yet · 1 not computed
When did Nervous System Autoimmune Disease, Experimental trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 2 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nervous System Autoimmune Disease, Experimental trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Not applicable | 3 |
How many Nervous System Autoimmune Disease, Experimental trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Nervous System Autoimmune Disease, Experimental? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The effect of mesenchymal stem cells on dynamic changes of T cell subsets in experimental autoimmune uveoretinitis. | Clinical and experimental immunology | 2013 | Yes |
| Beneficial role of rapamycin in experimental autoimmune myositis. | PloS one | 2013 | Yes |
| Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis. | European journal of heart failure | 2007 | Yes |
| Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. | Autonomic neuroscience : basic & clinical | 2009 | No |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, and rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.